Novel chemotherapeutic pro-drug approved for FIH trial in the UK
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
List view / Grid view
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
29 June 2012 | By kdm communications limited
Avacta Group has expanded its Yorkshire headquarters with the addition of new laboratory, office and manufacturing space...
8 April 2010 | By
Avacta Group, has chosen Tecan’s Infinite M200 microplate reader to play a pivotal role in offering innovative analytical services to the biopharmaceutical sector...